EICHORCondition: Solid Tumours · Sponsor: Orion Corporation, Orion Pharma
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Multi-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours
This description comes directly from the study's public registry record.
Clinical Study Director · +358104261 · clinicaltrials@orionpharma.com
Always discuss trial participation with your own doctor first.
| Valkyrie Clinical Trials | Los Angeles, California, United States | Recruiting |
| UC Irvine Health | Orange, California, United States | Recruiting |
| Siteman Cancer Center | St Louis, Missouri, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Westchester Medical Center | Valhalla, New York, United States | Recruiting |
| Jefferson University Hospital | Philadelphia, Pennsylvania, United States | Recruiting |
| University of Texas, MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| NEXT Virginia | Fairfax, Virginia, United States | Recruiting |
| Helsinki university Hospital | Helsinki, Finland | Recruiting |
| Oulu University Hospital | Oulu, Finland | Recruiting |
| Turku University Hospital | Turku, Finland | Recruiting |
| Institut Bergonie | Bordeaux, France | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06725758